Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) belonging to the Medical sector which declined -3.96% and closed its last trading session at $23.75.
The company reported its last EPS on 6/30/2016 and is expected to report its next EPS on 11/1/2016. Currently, the stock has a 1 Year Price Target of $27.67.
The consensus recommendation, according to Zacks Investment research, is 1.67. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell. The Stock had a 1.67 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 1.67 and 1 respectively.
Supernus Pharmaceuticals, Inc. on 6/30/2016 reported its EPS as $0.18 with the analysts projecting the EPS of the stock as $0.13. The company beat the analyst EPS Estimate with the difference of $0.05. This shows a surprise factor of 38.5%.
Many analysts have provided their estimated foresights on Supernus Pharmaceuticals, Inc. Earnings, with 5 analysts believing the company would generate an Average Estimate of $0.2. Whereas they predicted High and Low Earnings Estimate as $0.23 and $0.19 respectively. While in the same Quarter Previous year, the Actual EPS was $0.08.
Analysts are also projecting an Average Revenue Estimate for Supernus Pharmaceuticals, Inc. as $56.01 Million in the Current Quarter. This estimate is provided by 5 analysts. The High Revenue estimate is predicted as 58.3 Million, while the Low Revenue Estimate prediction stands at 54.4 Million. The company’s last year sales total was 38.59 Million.
For the Current Quarter, the growth estimate for Supernus Pharmaceuticals, Inc. is 150%, while for the Next Quarter the stock growth estimate is 50%. In the past 5 years, the stock showed growth of 0% per annum. While for the next 5 years, the growth estimate is 75%.
The Company got Downgrade by Piper Jaffray on 18-Jul-16 from Overweight to Neutral.
Insider Trades for Supernus Pharmaceuticals, Inc. show that the latest trade was made on 15 Sep 2016 where Patrick (Gregory S), the Chief Financial Officer completed a transaction type “Sell” in which 2000 shares were traded at a price of $25.
10 Insider Sales transactions were made totaling 304592 shares traded.
6 analysts projected Price Targets for Supernus Pharmaceuticals, Inc. The analysts believe that the company stock price could grow as high as $37. The Low Price target projection by analysts is $24 and the Mean Price Target is $27.67.
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) has the market capitalization of $1.17 Billion. The company rocked its 52-Week High of $26.84 on Sep 28, 2016 and touched its 52-Week Low of $9.51 on Feb 5, 2016. The stock has Return on Assets (ROA) of 13.6 percent. Return on Equity (ROE) stands at 21% and Return on Investment (ROI) of 11.4 percent.
The stock is currently showing YTD performance of 76.71 Percent. The company has Beta Value of 1.72 and ATR value of 1.05. The Weekly and Monthly Volatility stands at 5.28% and 4.24%.
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.